News Phase 3 readout puts Opthea at risk of insolvency After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.
News Marea’s $190m double round heads latest biotech financings Our latest round-up of biotech financings includes nine-figure rounds for Marea, Santa Ana Bio, and Opthea, with InduPro, Elion, and iOnctura also in on the action.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
